Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Long Term Debt of $339.88 million for the year ending 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +189.1% in Long Term Debt from 2024 to 2025.
- This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $48.67 million | Q3 2022: $48.98 million | Q1 2023: $83.97 million | Q2 2023: $99.25 million | Q3 2023: $114.73 million | Q1 2024: $116.14 million | Q2 2024: $116.61 million | Q3 2024: $117.09 million | Q1 2025: $118.01 million | Q2 2025: $118.38 million | Q3 2025: $339.75 million.
- Historical annual values: Fiscal year 2025: $339.88 million | Fiscal year 2024: $117.57 million | Fiscal year 2023: $115.48 million | Fiscal year 2022: $49.29 million | Fiscal year 2021: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: